Compare AFLAC Incorporated (AFL) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AFLAC Incorporated vs Crispr Therapeutics AG — how do they compare? AFLAC Incorporated trades at $121.41 (market cap $61.84B), while Crispr Therapeutics AG trades at $59.25 (market cap $5.98B). The key difference: AFLAC Incorporated is far larger — about 10.3× Crispr Therapeutics AG's market cap, and AFLAC Incorporated pays a 2.01% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| AFL | CRSP | |
|---|---|---|
Market Cap | $61.84B | $5.98B |
Sector | Financials | Health |
52-Week High | $121.49 | $76.78 |
52-Week Low | $98.09 | $44.34 |
Enterprise Value | $70.50B | $4.33B |
Dividend Yield | 2.01% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
